NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC), an innovative research model comprised of a network of 15 academic Member Institutions across North America and leadership in Norwalk, Connecticut, today announced preliminary data from an analysis showing that clinical trials opened through its clinical trials network were activated 30 to 40 percent faster than comparable clinical trials in oncology. Based on the implementation of specific business solutions, particularly scientific leadership, standardized clinical contracts and on-site project management resources, the MMRC has been able to decrease by an average of 100 days the time from the development and finalization of the trial’s protocol to actual patient enrollment.
